Abstract
Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium indologenes infections and antimicrobial susceptibilities of C indologenes. Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at a medical center, we analyzed the relationship between the prevalence of C indologenes infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic susceptibility, and outcomes. Results: Colistin and tigecycline were introduced into clinical use at this medical center since August 2006. The increasing numbers of patients with C indologenes pneumonia and bacteremia correlated to increased consumption of colistin ( p=0.018) or tigecycline ( p=0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate was 63.6% and 35.2% ( p=0.015), respectively. Administration of appropriate antibiotics showed significant benefit in 14-day survival in patients with C indologenes bloodstream infection ( p=0.040). In bacteremic patients, old cardiovascular accident ( p=0.036) and cancer ( p=0.014) were the most common comorbidity. The most common co-infection pathogen in patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6%), followed by Pseudomonas aeruginosa (23/91, 25.3%), carbapenem-resistant A baumannii (22/91, 24.2%), and Klebseilla pneumoniae (13/91, 14.3%). Antimicrobial susceptibility testing of the 215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%). Conclusion: The present study showed a trend of increasing prevalence of C indologenes infection after introduction of colistin and tigecycline usage. The bacteremia group had higher mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam, ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis. Trimethoprim-sulfamethoxazole was a potential antimicrobial agent invitro for C indologenes. To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.
| Original language | English |
|---|---|
| Pages (from-to) | 425-432 |
| Number of pages | 8 |
| Journal | Journal of Microbiology, Immunology and Infection |
| Volume | 46 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2013 |
Fingerprint
Keywords
- Chryseobacterium indologenes
- Colistin
- Tigecycline
- Trimethoprim-sulfamethoxazole
ASJC Scopus subject areas
- Microbiology (medical)
- Immunology and Allergy
- Immunology and Microbiology(all)
- Infectious Diseases
Cite this
Clinical and epidemiological features of Chryseobacterium indologenes infections : Analysisof 215 cases. / Chen, Fu Lun; Wang, Giueng Chueng; Teng, Sing On; Ou, Tsong Yih; Yu, Fang Lan; Lee, Wen Sen.
In: Journal of Microbiology, Immunology and Infection, Vol. 46, No. 6, 12.2013, p. 425-432.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical and epidemiological features of Chryseobacterium indologenes infections
T2 - Analysisof 215 cases
AU - Chen, Fu Lun
AU - Wang, Giueng Chueng
AU - Teng, Sing On
AU - Ou, Tsong Yih
AU - Yu, Fang Lan
AU - Lee, Wen Sen
PY - 2013/12
Y1 - 2013/12
N2 - Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium indologenes infections and antimicrobial susceptibilities of C indologenes. Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at a medical center, we analyzed the relationship between the prevalence of C indologenes infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic susceptibility, and outcomes. Results: Colistin and tigecycline were introduced into clinical use at this medical center since August 2006. The increasing numbers of patients with C indologenes pneumonia and bacteremia correlated to increased consumption of colistin ( p=0.018) or tigecycline ( p=0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate was 63.6% and 35.2% ( p=0.015), respectively. Administration of appropriate antibiotics showed significant benefit in 14-day survival in patients with C indologenes bloodstream infection ( p=0.040). In bacteremic patients, old cardiovascular accident ( p=0.036) and cancer ( p=0.014) were the most common comorbidity. The most common co-infection pathogen in patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6%), followed by Pseudomonas aeruginosa (23/91, 25.3%), carbapenem-resistant A baumannii (22/91, 24.2%), and Klebseilla pneumoniae (13/91, 14.3%). Antimicrobial susceptibility testing of the 215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%). Conclusion: The present study showed a trend of increasing prevalence of C indologenes infection after introduction of colistin and tigecycline usage. The bacteremia group had higher mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam, ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis. Trimethoprim-sulfamethoxazole was a potential antimicrobial agent invitro for C indologenes. To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.
AB - Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium indologenes infections and antimicrobial susceptibilities of C indologenes. Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at a medical center, we analyzed the relationship between the prevalence of C indologenes infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic susceptibility, and outcomes. Results: Colistin and tigecycline were introduced into clinical use at this medical center since August 2006. The increasing numbers of patients with C indologenes pneumonia and bacteremia correlated to increased consumption of colistin ( p=0.018) or tigecycline ( p=0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate was 63.6% and 35.2% ( p=0.015), respectively. Administration of appropriate antibiotics showed significant benefit in 14-day survival in patients with C indologenes bloodstream infection ( p=0.040). In bacteremic patients, old cardiovascular accident ( p=0.036) and cancer ( p=0.014) were the most common comorbidity. The most common co-infection pathogen in patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6%), followed by Pseudomonas aeruginosa (23/91, 25.3%), carbapenem-resistant A baumannii (22/91, 24.2%), and Klebseilla pneumoniae (13/91, 14.3%). Antimicrobial susceptibility testing of the 215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%). Conclusion: The present study showed a trend of increasing prevalence of C indologenes infection after introduction of colistin and tigecycline usage. The bacteremia group had higher mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam, ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis. Trimethoprim-sulfamethoxazole was a potential antimicrobial agent invitro for C indologenes. To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.
KW - Chryseobacterium indologenes
KW - Colistin
KW - Tigecycline
KW - Trimethoprim-sulfamethoxazole
UR - http://www.scopus.com/inward/record.url?scp=84889663753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84889663753&partnerID=8YFLogxK
U2 - 10.1016/j.jmii.2012.08.007
DO - 10.1016/j.jmii.2012.08.007
M3 - Article
C2 - 23022462
AN - SCOPUS:84889663753
VL - 46
SP - 425
EP - 432
JO - Journal of Microbiology, Immunology and Infection
JF - Journal of Microbiology, Immunology and Infection
SN - 0253-2662
IS - 6
ER -